Skip to Content

Radium 223 dichloride Disease Interactions

There are 2 disease interactions with radium 223 dichloride:


Radium Ra 223 (applies to radium 223 dichloride) myelosuppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

A randomized clinical trial reported that 2% of the patients receiving radium Ra 223 experienced bone marrow failure or ongoing pancytopenia, including 2 deaths due to bone marrow failure. Myelosuppression including thrombocytopenia, neutropenia, pancytopenia, and leukopenia have been reported in patients receiving this agent. Patients should have a baseline hematologic evaluation, as well as another evaluation prior to every dose. The absolute neutrophil count (ANC) prior to the first administration should be >= 1.5 x 10^9/L, the platelet count should be >= 100 x 10^9/L, and hemoglobin should be >= 10 g/dL; and before subsequent administrations, the ANC should be >= 1 x 10^9/L and the platelet count >= 50 x 10^9/L. Discontinue treatment if after the last administration there is no recovery of these values within 6 to 8 weeks, despite supporting care and in those patients experiencing life-threatening complications. Caution is advised in patients with preexisting hematologic issues.


Radium Ra 223 (applies to radium 223 dichloride) renal/hepatic

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223. Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment. No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment. Caution is advised if used in these patients.

Radium 223 dichloride drug interactions

There are 190 drug interactions with radium 223 dichloride

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.